HC Wainwright restated their buy rating on shares of Palvella Therapeutics (NASDAQ:PVLA - Free Report) in a research report report published on Tuesday,Benzinga reports. The brokerage currently has a $38.00 price target on the stock.
Other analysts have also recently issued research reports about the stock. TD Cowen started coverage on shares of Palvella Therapeutics in a report on Wednesday, February 5th. They issued a "buy" rating and a $44.00 price objective on the stock. Cantor Fitzgerald started coverage on shares of Palvella Therapeutics in a report on Wednesday, December 18th. They issued an "overweight" rating on the stock.
Check Out Our Latest Analysis on Palvella Therapeutics
Palvella Therapeutics Stock Down 2.2 %
Shares of PVLA stock traded down $0.44 during trading hours on Tuesday, reaching $19.56. The stock had a trading volume of 81,054 shares, compared to its average volume of 51,451. Palvella Therapeutics has a twelve month low of $6.20 and a twelve month high of $22.32. The company's 50-day simple moving average is $13.30. The company has a market cap of $219.46 million, a price-to-earnings ratio of -1.62 and a beta of 0.68.
Insider Buying and Selling at Palvella Therapeutics
In related news, Director George M. Jenkins bought 4,000 shares of the stock in a transaction on Wednesday, December 18th. The shares were purchased at an average price of $12.93 per share, with a total value of $51,720.00. Following the purchase, the director now owns 180,671 shares in the company, valued at approximately $2,336,076.03. This represents a 2.26 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.39% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Palvella Therapeutics
Several large investors have recently bought and sold shares of the stock. Blue Owl Capital Holdings LP acquired a new position in Palvella Therapeutics during the 4th quarter valued at about $3,001,000. ADAR1 Capital Management LLC bought a new position in shares of Palvella Therapeutics during the 4th quarter valued at about $1,736,000. BML Capital Management LLC bought a new position in shares of Palvella Therapeutics during the 4th quarter valued at about $506,000. Renaissance Technologies LLC bought a new position in shares of Palvella Therapeutics during the 4th quarter valued at about $256,000. Finally, Geode Capital Management LLC bought a new position in shares of Palvella Therapeutics during the 4th quarter valued at about $171,000. Institutional investors and hedge funds own 40.11% of the company's stock.
Palvella Therapeutics Company Profile
(
Get Free Report)
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.
Featured Stories
Before you consider Palvella Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palvella Therapeutics wasn't on the list.
While Palvella Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
